Lambregts, Doenja M. J. http://orcid.org/0000-0003-2990-0099
Maas, Monique
Boellaard, Thierry N.
Delli Pizzi, Andrea
van der Sande, Marit E.
Hupkens, Britt J. P.
Lahaye, Max J.
Bakers, Frans C. H.
Beets, Geerard L.
Beets-Tan, Regina G. H.
Article History
Received: 3 April 2019
Revised: 24 June 2019
Accepted: 26 July 2019
First Online: 19 August 2019
Compliance with ethical standards
:
: The scientific guarantor of this publication is Doenja Lambregts.
: The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
: No complex statistical methods were necessary for this paper.
: Written informed consent was waived by the Institutional Review Board.
: Institutional Review Board approval was obtained.
: The study patients were all selected from consecutive cohorts of previously reported and ongoing clinical trials focussing on the oncological and functional outcome of a watch-and-wait policy (Maas et al JCO 2011, Martens et al J Natl Cancer Inst 2016, van der Valk et al Lancet 2018, and an ongoing clinical study registered at clinical trials.gov under NCT03426397). In addition, 47 of the patients included in the current study were included in a previous study on the use of MRI+DWI to detect local tumour regrowths during follow-up (Lambregts et al Eur Rad 2016). This previous study concerned a diagnostic accuracy study focussing on detecting recurrent tumours with a specific focus on DWI, while the current report is a descriptive study focussing on T2W morphology which included only non-recurrent patients.
: • Retrospective• Diagnostic or prognostic study• Multicentre study